The treatment, management and prevention of oesophageal cancer

Bibliography

• Health Statistics Quarterly. Winter 2000.
   Google Scholar
• POWELL J, McCONKEY CC: The rising trend in oesophageal adenocarcinoma and gastric cardia. Eur. I Cancer Prey. (1992) 1:265–269.
   PubMedGoogle Scholar
• REYNOLDS JC, WARONKER M, PACQUING MS, YASSIN RR: Barrett's esophagus: reducing the risk of progression to adenocarcinoma. Gastroenterol OM North America (1999) 28:917–945.
   PubMed Web of Science ®Google Scholar
• CORLEY DA, BUFFLER PA: Esophageal and gastric cardia adenocarcinomas: analysis of regional variation using the cancer incidence in five continents database. Int. Epidemiol (2001) In press.
   Google Scholar
• JANKOWSKI JA, HARRISON R, PERRY I, BALKWILL F, TSELEPIS C: Barrett's metaplasia. Lancet (2000) 356:2079–2085.
   PubMed Web of Science ®Google Scholar
• ••A thorough review of Barrett's metaplasia.
   Google Scholar
• WESTON AE BADR AS, TOPALOVSKI M, CHERIAN R, DIXON A, HASSANEIN RS: Prospective evaluation of the prevalence of gastric helicobacter pylori infection in patients with GERD, Barrett's esophagus, Barrett's dysplasia and Barrett's adenocarcinoma. Am. j Gastroenterol (2000) 95:387–394.
   PubMed Web of Science ®Google Scholar
• VAN SANDICK JW, VAN LANSCHOTJJB, KUIKEN BW, TYTGAT GNJ, OFFERHUAS GJA, OBERTOP H: Impact of endoscopic biopsy surveillance of Barrett's oesophagus on pathological stage and clinical outcome. Gut (1998) 43:216–222.
   PubMed Web of Science ®Google Scholar
• STREITZ JM, ELLIS FH, TILDEN RL, ERICKSON RV: Endoscopic surveillance of Barrett's esophagus: a cost effectiveness comparison with mammographic surveillance for breast cancer. Am. j Gastroenterol (1998) 93:911–915.
   PubMed Web of Science ®Google Scholar
• IFTIKHAR SY, JAMES PD, STEELE RJC: Length of Barrett's oesophagus: an important factor in the development of dysplasia and adenocarcinoma. Gut (1992) 33:1155–1158.
   PubMed Web of Science ®Google Scholar
• MOORE KH, BARRY P, BURN J, FALK G: Adenocarcinoma of the rat esophagus in the presence of a proton pump inhibitor: a pilot study. Dis. Esophagus (2001) 14:17–22.
   PubMed Web of Science ®Google Scholar
• TRIADAFILOPOULOS G: Proton pump inhibitors for Barrett's oesophagus. Gut (2000) 46:144–146.
   PubMed Web of Science ®Google Scholar
• PETERS FTM, GANESH S, KUIPERS EJ etal.: Endoscopic regression of Barrett's oesophagus during omeprazole treatment; a randomised double blind study. Gut (1999) 45:489–494.
   Google Scholar
• OATU-LASCAR R, FITZGERALD RC, TRIADAFILOPOULOS G: Differentiation and proliferation in Barrett's esophagus and the effect of acid suppression. Gastroenterology (1999) 117:327–335.
   PubMed Web of Science ®Google Scholar
• OATU-LAS CARR, TRIADAFILOPOULOS G: Complete elimination of reflux symptoms does not guarantee normalization of intraesophageal acid reflux in patients with Barrett's esophagus. Am. I Gastroenterol (1998) 93:711–716.
   PubMed Web of Science ®Google Scholar
• SOUZA RE SHEWMAKE K, TERADA LS, SPECHLER SJ: Acid induces mitogen activated protein kinase (MAPK) activation and decreases apoptosis in human esophageal adenocarcinoma cells. Gastroenterology (2001) 120\(Suppl. 1):A3588.
   Google Scholar
• LAGERGREN J, BERGSTROM R, LINDGREN A, NYREN 0: Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Eng] j Med. (1999) 340:825–831.
   PubMed Web of Science ®Google Scholar
• SHARMA P, SAMPLINER R: GERD, DGER, or both in Barrett's esophagus? Am. Gastroenterol (1997) 92:903–904.
   Google Scholar
• JANKOWSKI JA, HOPWOOD D, PRINGLE R, WORMSLEY K: Increased expression of EGFR in Barrett's esophagus associated with alkaline reflux: a putative model for carcinogenesis. Am. Gastroenterol (1993) 56:1480–1483.
   Google Scholar
• GILLEN P, KEELING P, BYRNE PJ, HEALY M, O'MOORE RR, HENNESSY TP: Implication of duodenogastric reflux in the pathogenesis of Barrett's oesophagus. Br Surg. (1988) 75:540–543.
   PubMed Web of Science ®Google Scholar
• TSELEPIS C, PERRY I, BOULTON R Endogenous secondary bile acid levels modify epithelial biology in Barrett's oesophagus. Gut (1999) 45:A238.
   Google Scholar
• VAN LAETHEM JL, CREMER M, PENY MO, DELHAYE M, DEVIERE J: Eradication of Barrett's mucosa with argon plasma coagulation and acid suppression: immediate and mid term results. Gut (1998) 43:747–751.
   PubMed Web of Science ®Google Scholar
• VAN LAETHEM JL, PENY MO, SALMON I, CREMER M, DEVIERE J: Intramucosal adenocarcinoma arising under squamous re-epithelialisation of Barrett's oesophagus. Gut (2000) 46:574–577.
   PubMed Web of Science ®Google Scholar
• KRISHNADATH la, WANG KK, TANIGUCHI K et al.: Persistent genetic abnormalities in Barrett's esophagus after photodynamic therapy. Gastroenterology (2000) 119:624–630.
   PubMed Web of Science ®Google Scholar
• KRISHNADATH la, WANG KK, TANIGUCHI K et al: P53 mutations in Barrett's esophagus predict poor response to photodynamic therapy. Gastroenterology (2001) 120\(Suppl. 1):A2111.
   Google Scholar
• WILSON KT, FU S, RAMANUJAM KS, MELTZER SJ: Increased expression of inducible nitric oxide synthase and cyclooxygenase 2 in Barrett's oesophagus and associated adenocarcinomas. Cancer Res. (1998) 58:2929–2934.
   PubMed Web of Science ®Google Scholar
• SHAMMA A, YAMAMOTO H, DOKI Y et al: Up-regulation of cyclo-oxygenase-2 in squamous carcinogenesis of the esophagus. Clin. Can. Res. (2000) 6:1229–1238.
   PubMed Web of Science ®Google Scholar
• KANDIL HM, TANNER G, SMALLEY W HALTERS, ARAMANDALA R, DUBOIS RN: Cyclooxygenase-2 expression in Barrett's esophagus. Dig. Dis. Sri. (2001) 46:785–789.
   PubMed Web of Science ®Google Scholar
• SHIRVANI V, OATU-LAS CARR, KAURBS, OMARY B, TRIADAFILOPOULOS G: Cyclooxygenase 2 expression in Barrett's esophagus and adenocarcinoma: ex vivo induction by bile salts and acid exposure. Gastroenterology (2000) 118:487–496.
   PubMed Web of Science ®Google Scholar
• •Demonstrates the relevance of both bile acids and COX-2.
   Google Scholar
• LIU CH, CHANG S, NARKO K et al: Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. I Biol. Chem. (2001) 276:18563–18569.
   Web of Science ®Google Scholar
• JACOBY RF, SEIBERT K, COLE CE, KELLOFF G, LUBET RA: The cyclooxygenase-2 inhibitor is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. Cancer Res. (2000) 60:5040–5044.
   PubMed Web of Science ®Google Scholar
• STEINBACH G, LYNCH PM, PHILLIPS RKS etal.: The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl. j. Med. (2000) 342:1946–1952.
   Google Scholar
• SOUZA RE SHEWMAKE K, BEER DG, CRYER B, SPECHLER SJ: Selective inhibition of cyclooxygenase-2 suppresses growth and induces apoptosis in human esophageal adenocarcinoma cells. Cancer Res. (2000) 60:5767–5772.
   PubMed Web of Science ®Google Scholar
• NGUYEN NT, SCHAUER P, LUKETICH JD: Minimally invasive esophagectomy for Barrett's esophagus with high-grade dysplasia. Surgery (2000) 127:284–290.
   PubMed Web of Science ®Google Scholar
• GOSSNER L, STOLTE M, SROKA R et al.: Photodynamic ablation of high-grade dysplasia and early cancer in Barrett's esophagus by means of 5-aminolevulinic acid. Gastroenterology (1998) 114:448–455.
   PubMed Web of Science ®Google Scholar
• ACKROYD R, BROWN NJ, DAVIS MF et al.: Photodynamic therapy for dysplastic Barrett's oesophagus: a prospective, double blind, randomised, placebo controlled trial. Gut (2000) 47:612–617.
   PubMed Web of Science ®Google Scholar
• BARR H, SHEPHERD N, DIX A et al: Eradication of high-grade dysplasia in columnar lined (Barrett's) oesophagus by photodynamic therapy with endogenously generated protoporphyrin IX. Lancet (1996) 348:584–585.
   PubMed Web of Science ®Google Scholar
• TAKEKOSHI T, BABA Y, OTA H etal.: Endoscopic resection of early gastric carcinoma: results of a retrospective analysis of 308 cases. Endoscopy (1994) 26:352–358.
   Google Scholar
• ELL C, MAYA, GOSSNER L et al: Endoscopic mucosal resection of early cancer and high-grade dysplasia in Barrett's esophagus. Gastroenterology (2000) 118:670–677.
   PubMed Web of Science ®Google Scholar
• EARLAM R, CUNHA-MELO JR: Oesophageal squamous cell carcinoma: I. A critical review of surgery. Br. I Surg. (1980) 67:381–390.
   PubMed Web of Science ®Google Scholar
• LEIRUT T, COOSEMANS W, DE LEYN P, VAN RAEMDONCK D, DENEFFE G, DECKER G. Treatment of esophageal carcinoma. Chest (1999) 116:463S–464S.
   Google Scholar
• RICE TW: Clinical staging of esophagealcarcinoma. CT, EUS, and PET. Chest Surg. N Am. (2000) 10:471–485.
   PubMedGoogle Scholar
• LIGHTDALE CJ: Indications, contraindications, and complications of endoscopic ultrasonography. Gastrointest. Endoscopy (1996) 43:S15–19.
   PubMed Web of Science ®Google Scholar
• RICHARDS DG, BROWN TH, MANSON J: Endoscopic ultrasound in the staging of tumours of the oesophagus and gastro-oesophageal junction. Ann. R. Coll. Surg. Engl. (2000) 82:311–317.
   PubMed Web of Science ®Google Scholar
• SHINKAI M, NIWA Y, ARISAWA T, OHMIYA N, GOTO H, HAYAKAWA T: Evaluation of prognosis of squamous cell carcinoma of the oesophagus by endoscopic ultrasonography. Gut (2000) 47:120–125.
   PubMed Web of Science ®Google Scholar
• KRASNA MI, REED CE, NEDZWIECKI D et al: CALGB 9380: A prospective trial of the feasibility of thoracoscopy/ laparoscopy in staging esophageal cancer. Ann. Thorac. Surg. (2001) 71:1073–1079.
   PubMed Web of Science ®Google Scholar
• LUKETICH JD, SCHAUER PR, MELTZER CC, LANDRENEAU RJ, URSO K, TOWNSEND DW: Role of positron emission tomography in staging oesophageal cancer. Ann. Thorc. Surg. (1997) 64:765–769.
   PubMed Web of Science ®Google Scholar
• MELTZER CC, LUKETICH JD, FRIEDMAN D et al: Whole body FDG positron emission tomography imaging for staging esophageal cancer comparison with computed tomography. CM]. Nucl. Med. (2000) 25:882–887.
   PubMed Web of Science ®Google Scholar
• LERUT T, FLAMEN P, ECTORS N et al: Histopathologic validation of lymph node staging with FDG-PET scan in cancer of the esophagus and gastroesophageal junction. Ann. Surg. (2000) 232:743–752.
   PubMed Web of Science ®Google Scholar
• LEHNERT T: Multimodal therapy for squamous carcinoma of the oesophagus. Br Surg. (1999) 86:727–739.
   PubMed Web of Science ®Google Scholar
• POULIQUEN X, LEVARD H, HAY JM, MCGEE K, FINGERHUT A, LANGLOIS-ZANTIN 0: 5-Fluorouracil and cisplatin therapy after palliative surgical resection of squamous cell carcinoma of the esophagus. Ann. Surg. (1996) 223:127–133.
   PubMed Web of Science ®Google Scholar
• ANDO N, IIZUKA T, KAKEGAWA T et al.: A randomised trial of surgery with and without chemotherapy for localised squamous carcinoma of the thoracic esophagus: the Japan Clinical Oncology Group Study. j. Thorac. Cardiovasc. Surg. (1997) 114:205–209.
   PubMed Web of Science ®Google Scholar
• ARNOTT SJ, DUNCAN W, GIGNOUX M et al.: Preoperative radiotherapy in esophageal carcinoma: a meta-analysis using individual patient data (Oesophageal Cancer Collaborative Group). Int. j. Radiat. arca Biol. Phys. (1998) 41:579–583.
   PubMed Web of Science ®Google Scholar
• KELSEN DP, GINSBERG R, PAJAK TF et al.: Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl. j. Med. (1998) 339:1979–1984.
   PubMed Web of Science ®Google Scholar
• MEDICAL RESEARCH COUNCIL (MRC) UPPER GI TRACT CANCER GROUP: Medical Research Council randomised Phase III trial of surgery with or without preoperative chemotherapy in resectable cancer of the oesophagus. Br j. Cancer (2000) 83\(Suppl. 1):1.
   Google Scholar
• MALTHANER R, FENLON D: Preoperative chemotherapy for resectable Expert Op/n. Biol. Ther. (2001) 1(6) thoracic esophageal cancer (cochrane review). Cochrane Database Syst. Rev (2001) 1:CD001556.
   Google Scholar
• GEH JI, CRELLIN AM, GLYNNE-JONES R: Preoperative (neoadjuvant) chemoradiotherapy in oesophageal cancer. Br .j Surg. (2001) 88:338–356.
   PubMed Web of Science ®Google Scholar
• BOSSET JF, GIGNOUX M, TRIBOULET JP et al.: Chemoradiotherapy followed by surgery compared with surgery alone in squamous cell cancer of the esophagus. N Engl. J Med. (1997) 337:161–167.
   PubMed Web of Science ®Google Scholar
• WALSH TN, NOONAN N, HOLLYWOOD D, KELLY A, KEELING N, HENNESSY TPJ: A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl. J Med. (1996) 335:462–467.
   PubMed Web of Science ®Google Scholar
• •Useful review of neoadjuvant therapy.
   Google Scholar
• URBA SG, ORRINGER MB, TURRISI A, IANNETTONI M, FORASTIERE A, STRAWDERMAN M: Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin. Oncol. (2001) 19:305–313.
   PubMed Web of Science ®Google Scholar
• ILSON DH, FORASTIERE A, ARQUETTE M etal.: A Phase II trial of paclitaxel and cisplatin in patients with advanced carcinoma of the esophagus. Cancer J. (2000) 6:316–323.
   Google Scholar
• SAFRAN H, GAISSERT H, AKERMAN P et al.: Paclitaxel, cisplatin, and concurrent radiation for esophageal cancer. Cancer Invest. (2001) 19:1–7.
   PubMed Web of Science ®Google Scholar
• PHILIP P, ZALUPSKI M, GAD GEEL, HUSSAIN M, SHIELDS A: A Phase II study of carboplatin and paclitaxel in the treatment of patients with advanced esophageal and gastric cancer. Semi]. Oricol. (1997) 24(519):86–88.
   Google Scholar
• PRICE T, HILL M, NORMAN A, SUMPTER K, CUNNINGHAM D: The Royal Marsden experience of the use of carboplatin in oesophageal carcinoma. Gastr. Oricol. (2001) In press.
   Google Scholar
• DEPALMA GD, DI MATTEO E, ROMANO G, FIMMANO A, RONDINONE G, CATANZANO C: Plastic prosthesis versus expandable metal stents for palliation of inoperable esophageal thoracic carcinoma: a controlled prospective study. Gastrointest. Enclose. (1996) 43:478–482.
   PubMed Web of Science ®Google Scholar
• RATE AJ, NICHOLSON DA, BROWN TH, KAY CL, BANCEWICZ J: Palliation of oesophageal carcinoma with expandable metal prosthesis is a cost effective procedure. Edinburgh: British Sot:leo, of Gastroenterology September (1994).
   Google Scholar
• ADAM A, ELLUL J, WATKINSON AF et al.: Palliation of inoperable esophageal carcinoma: a prospective randomised trial of laser therapy and stent placement. Radiology (1997) 202:344–348.
   PubMed Web of Science ®Google Scholar
• DALLAL HJ, GRIEVE D, GHOSH S, PENMAN I, PALMER KR: Expandable metallic stents versus Nd-YAG laser therapy for the palliative treatment of oesophageal cancer: a randomised trial. Gut (1998) 42\(Suppl. 1):TW265.
   Google Scholar
• SARGEANT IR, TOBIAS JS, BLACKMAN G et al. Radiotherapy enhances laser palliation of malignant dysphagia: a randomised study. Gut (1997) 40:362–369.
   PubMed Web of Science ®Google Scholar
• JANKOWSKI JA, WRIGHT NA, MELTZER SJ et al.: Molecular evolution of the metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. Am. J Pathol. (1999) 154:965–974.
   PubMed Web of Science ®Google Scholar
• BRITO MJ, FILIPE MI, LINEHAN J, JANKOWSKI J: Association of transforming growth factor alpha and its precursors with malignant change in Barrett's epithelium: biological and clinical variables. Int. Jour. Cancer (1995) 60:27–32.
   PubMed Web of Science ®Google Scholar
• BAILEY T, BIDDLESTONE L, SHEPHERD N, BARR H, WARNER P, JANKOWSKI J: Altered cadherin and catenin complexes in the Barrett's esophagus-dysplasia-adenocarcinoma sequence: correlation with disease progression and dedifferentiation. Am. J. Pathol. (1998) 152:135–144.
   PubMed Web of Science ®Google Scholar
• KARNES W, WELLER S, ADJEI P et al.: Inhibition of epidermal growth factor receptor kinase induces protease dependent apoptosis in human colon cancer cells. Gastroenterology (1998) 114:930–939.
   PubMed Web of Science ®Google Scholar
• RITLAND SR, GENDLER SJ, BURGART LJ et al.: Inhibition of epidermal growth factor receptor tyrosine kinase fails to suppress adenoma formation in APC min mice but induces duodenal injury. Cancer Res. (2000) 60:4678–4681.
   PubMed Web of Science ®Google Scholar
• CIARDIELLO F, CAPUTO R, BIANCO R et al.: Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin. Cancer Res. (2000) 6:2053–2063.
   PubMed Web of Science ®Google Scholar
• JANKOWSKI JA, COGHILL G, HOPWOOD D, WORMSLEY KG: Oncogenes and onco-suppressor gene in adenocarcinoma of the oesophagus. Gut (1992) 33:1033–1038.
   PubMed Web of Science ®Google Scholar
• AL-KASSPOOLES M, MOORE JH, ORRINGER MB, BEER DG: Amplification and over-expression of the EGFR and erbB-2 genes in human esophageal adenocarcinomas. Int. J Cancer (1993) 54:213–219.
   PubMed Web of Science ®Google Scholar
• •Iressa has promise of being an important therapy.
   Google Scholar
• MANN M, SHENG H, SHAO J et al.: Targeting cyclooxygenase2 and her-2/neu pathways inhibits colorectal carcinoma growth. Gastroenterology (2001) 120: 1713-1719.
   Google Scholar
• TORRANCE CJ, JACKSON PE, MONTGOMERY E et al.: Combinatorial chemoprevention of intestinal neoplasia. Nature Med. (2000) 6:1024–1028.
   PubMed Web of Science ®Google Scholar
• COFFEY RJ, HAWKEY CJ, DAMSTRUP L et al.: Epidermal growth factor receptor activation induces nuclear targeting of cyclooxygenase-2, basolateral release of prostaglandins, and mitogenesis in polarizing colon cancer cells. Proc. Nati Acad. Sci. USA (1997) 94:657–662.
   PubMed Web of Science ®Google Scholar
• GUPTA RA, DUBOIS RN: Combinationsfor cancer prevention. Nature Med. (2000) 6:974–975.
   PubMed Web of Science ®Google Scholar
• PAPADAKIS KA, TARGAN SR: Tumour necrosis factor: biology and therapeutic inhibitors. Gastroenterology (2000) 119:1148–1157.
   PubMed Web of Science ®Google Scholar
• WANG JM, DENG X, GONG W, SU S: Chemokines and their role in tumor growth and metastasis. J Immunol. Methods (1998) 220:1–17.
   PubMed Web of Science ®Google Scholar
• ••The combinatorial approach to chemoprevention is an important concept.
   Google Scholar
• PERRY I, TSELEPIS C, HARDY R et al.: TNF alpha induces elevated levels of nuclear TCF/beta catenin complexes in a colon cancer cell line. Gut (2000) 46(Suppl):1–5.
   Google Scholar
• HASHIMOTO M: Fundamental and clinical investigations on immunochemotherapy for esophageal cancer. Investigations on the adoptive immunotherapy using LAK cells. Akita J Med. (1985) 12:657–674.
   Google Scholar
• MATSUZAKI I, SUZUKI H, KITAMURA M et al.: Cisplatin induces fas expression in esophageal cancer cell lines and enhanced cytotoxicity in combination with LAK cells. Expert Op/n. Biol. Ther. (2001) 1(6) Oncology (2000) 59:336–343.
   Google Scholar
• MATSUBARA H, MAEDA T, GUNJI Y et al.: Combinatory anti-tumor effects of electroporation-mediated chemotherapy and wild-type gene transfer to human esophageal cancer cells. Int. j Oncol (2001) 18:825–829.
   PubMed Web of Science ®Google Scholar
• ISHII H, DUMON KR, VECCHIONE A et al: Effect of adenoviral transduction of the fragile histidine triad gene into esophageal cancer cells. Cancer Res. (2001) 61:1578–1584.
   PubMed Web of Science ®Google Scholar
• SCHMID RM, WEIDENBACH H, DRAENERT GF, LIPTAY S, LUHRS H, ADLER G: Liposome mediated gene transfer into the rat oesophagus. Gut (1997) 41:549–556.
   PubMed Web of Science ®Google Scholar
• ORDITURA M, DE VITA F, BELLI A et al.: Efficacy and safety profile of amifostine in the preoperative combined therapy of esophageal cancer patients. Oncol Rep. (2000) 7:397–400.
   PubMed Web of Science ®Google Scholar